Calliditas Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Renee Aguiar-Lucander
Chief executive officer
kr18.4m
Total compensation
| CEO salary percentage | 36.6% |
| CEO tenure | 7yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3.2yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Is Calliditas Therapeutics (STO:CALTX) A Risky Investment?
Apr 24Need To Know: The Consensus Just Cut Its Calliditas Therapeutics AB (publ) (STO:CALTX) Estimates For 2022
Mar 19Analysts' Revenue Estimates For Calliditas Therapeutics AB (publ) (STO:CALTX) Are Surging Higher
Feb 28Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr18m | kr7m | -kr466m |
| Sep 30 2023 | n/a | n/a | -kr451m |
| Jun 30 2023 | n/a | n/a | -kr292m |
| Mar 31 2023 | n/a | n/a | -kr393m |
| Dec 31 2022 | kr13m | kr6m | -kr412m |
| Sep 30 2022 | n/a | n/a | -kr628m |
| Jun 30 2022 | n/a | n/a | -kr608m |
| Mar 31 2022 | n/a | n/a | -kr576m |
| Dec 31 2021 | kr11m | kr5m | -kr500m |
| Sep 30 2021 | n/a | n/a | -kr452m |
| Jun 30 2021 | n/a | n/a | -kr600m |
| Mar 31 2021 | n/a | n/a | -kr501m |
| Dec 31 2020 | kr7m | kr3m | -kr433m |
| Sep 30 2020 | n/a | n/a | -kr286m |
| Jun 30 2020 | n/a | n/a | -kr198m |
| Mar 31 2020 | n/a | n/a | -kr54m |
| Dec 31 2019 | kr4m | kr3m | -kr33m |
| Sep 30 2019 | n/a | n/a | -kr54m |
| Jun 30 2019 | n/a | n/a | -kr35m |
| Mar 31 2019 | n/a | n/a | -kr136m |
| Dec 31 2018 | kr4m | kr2m | -kr132m |
Compensation vs Market: Renee's total compensation ($USD1.72M) is above average for companies of similar size in the Swedish market ($USD591.94K).
Compensation vs Earnings: Renee's compensation has increased whilst the company is unprofitable.
CEO
Renee Aguiar-Lucander (61 yo)
7yrs
Tenure
kr18,367,000
Compensation
Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 7yrs | kr18.37m | 1.2% SEK 75.6m | |
| Chief Financial Officer | 6.8yrs | no data | 0.080% SEK 5.0m | |
| Head of Technical Operations | 1.3yrs | no data | no data | |
| Head of IR & Sustainability | 1.3yrs | no data | no data | |
| Group General Counsel | 1.3yrs | no data | no data | |
| Head of Human Resources | 4.3yrs | no data | no data | |
| Head of Clinical Development & VP of Project Management | 7.3yrs | no data | no data | |
| Chief Medical Officer | 3.8yrs | no data | no data | |
| Head of US Marketing | 3.2yrs | no data | no data | |
| Head of US Sales | 3.2yrs | no data | no data | |
| President of North America | less than a year | no data | no data | |
| Vice President of Market Access | no data | no data | no data |
3.2yrs
Average Tenure
48yo
Average Age
Experienced Management: CALTX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Director | 5yrs | kr795.00k | 0.031% SEK 2.0m | |
| Independent Chairman | 5yrs | kr1.74m | 0.086% SEK 5.4m | |
| Independent Non-Executive Director | 2yrs | kr762.00k | 0.019% SEK 1.2m | |
| Independent Director | 2yrs | kr587.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 9.7yrs | kr731.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.0yrs
Average Tenure
64yo
Average Age
Experienced Board: CALTX's board of directors are considered experienced (5 years average tenure).